Washington, D.C. 20549






July 24, 2023



Commission File Number: 001-39363




Paul-Ehrlich-Straße 15

72076 Tübingen, Federal Republic of Germany

(Address of principal executive office)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:


Form 20-F

  Form 40-F









On July 19, 2023, Immatics N.V. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Bristol-Myers Squibb Company (the “Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchaser and the Purchaser agreed to purchase from the Company 2,419,818 ordinary shares at $14.4639 per share. The closing of this transaction occurred on July 21, 2023. The Securities Purchase Agreement includes the terms and conditions for the sale of the ordinary shares and other terms and conditions customary in agreements of this type. In the Securities Purchase Agreement, the Company agreed to file, within 60 calendar days, a registration statement on Form F-3 that registers for resale under the Securities Act the ordinary shares sold under the Securities Purchase Agreement. The Company will be required to keep such registration statement effective until all such ordinary shares have been sold pursuant to such registration statement or Rule 144 under the Securities Act, are eligible to be immediately sold to the public without registration or restriction, are no longer outstanding or one year has passed from their issuance.


On July 19, 2023, the Company entered into an information rights agreement with the Purchaser, pursuant to which the Company granted the Purchaser the right to designate one member of the Company’s Scientific Advisory Board.




This Report on Form 6-K (other than Exhibit 99.1) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-258351 and 333-240260) of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.




Exhibit No. Description
99.1 Press release dated July 24, 2023







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: July 24, 2023  
  By: /s/ Harpreet Singh
  Name: Harpreet Singh
  Title: Chief Executive Officer











Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb


Tuebingen, Germany and Houston, TX July 24, 2023Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that Bristol Myers Squibb (NYSE: BMY) has made a $35 million equity investment in Immatics. Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of $14.461. Additionally, Bristol Myers Squibb has the right to appoint a member to the Immatics Scientific Advisory Board.


“This investment is further testimony to the strength of the relationship and of our differentiated platform technologies that are the foundation of our TCR-based cell therapies and bispecifics,” commented Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics. “We remain steadfast in our commitment to advancing innovative treatment options for patients in their fight against cancer, and look forward to providing further clinical results in the second half of the year.”


The securities referenced above have not been registered under the Securities Act of 1933, as amended, or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws.


– END –


About Immatics


Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.


For regular updates about Immatics, visit www.immatics.com. You can also follow us on Instagram, Twitter and LinkedIn.



1Exact price per share $14.4639



Immatics Press Release July 24, 20231 | 2


Forward-Looking Statements:


Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics’ future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics’ focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the SEC. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.


For more information, please contact:


Media and Investor Relations Contact
Eva Mulder or Charlotte Spitz  
Trophic Communications  
Phone: +31 6 52 33 15 79  


Immatics N.V.  
Anja Heuer Jordan Silverstein
Senior Director, Corporate Communications Head of Strategy
Phone: +49 89 540415-606 Phone: +1 281 810 7545
media@immatics.com InvestorRelations@immatics.com



Immatics Press Release July 24, 20232 | 2